Novo Nordisk offers Wegovy and Ozempic at $199/month for new self-pay patients, valid for the first two months until March 31 ...

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Novo Nordisk announced that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients.

For a limited time, patients in the US can get the first two doses of authentic, FDA-approved Wegovy(R) and Ozempic(R) for only $199 each beginning November 17, 2025 -- Also effective November 17, ...

President Trump wants to cut the price of Ozempic to $150. While that could be an issue for Novo Nordisk, it should find a way to navigate ongoing price negotiations. 10 stocks we like better than ...

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks of the year ...

If developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) were a poker game, you could say Novo Nordisk (NASDAQ Copenhagen: NOVO-B) saw a competitor’s bet and raised the stakes ...

Novo Nordisk can reach MASH patients with the recent FDA decision expanding approval of its GLP-1 drug Wegovy to the treatment of moderate-to-advanced cases of the fatty liver disease. Now it’s ...

Novo Nordisk A/S agreed to buy Akero Therapeutics Inc. for as much as $5.2 billion to expand its portfolio in a type of liver disease that’s linked to obesity. Novo will pay $54 a share in cash, ...

Novo Nordisk NOVO.B2.66%increase; green up pointing triangle agreed to acquire Akero Therapeutics AKRO 0.24%increase; green up pointing triangle for up to $5.2 billion in cash. Under the terms of the ...

Novo Nordisk, the Danish drug manufacturer behind the weight-loss and diabetes drug Ozempic and other medications, said it’s paying up to $5.2 billion to buy Akero Therapeutics, a biotech company with ...